Personalized Opioid Overdose Rescue and Prevention Platform
Legal Citation
Summary of the Inventive Concept
A next-generation opioid overdose rescue and prevention system that leverages AI, wearable devices, and nanoparticle formulations to provide personalized, proactive, and effective treatment solutions.
Background and Problem Solved
The original patent addressed the need for opioid antagonist delivery, but it had limitations in terms of treatment timing, dosage, and patient-specific needs. The new inventive concept addresses these limitations by integrating AI-powered decision support, wearable devices, and nanoparticle formulations to provide a more comprehensive and effective solution for opioid overdose rescue and prevention.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for personalized opioid overdose rescue, including a wearable device configured to detect opioid exposure, a micro-needle injector containing a tailored dose of an opioid antagonist, and an AI-powered decision support module to optimize treatment parameters based on individual patient characteristics. The system also includes a method for predictive opioid overdose prevention, utilizing machine learning algorithms to identify high-risk individuals and optimize treatment timing and dosage. Additionally, the inventive concept encompasses a novel opioid antagonist formulation comprising nanoparticle-encapsulated active agents, designed to target specific opioid receptors in the brain and provide enhanced bioavailability and reduced side effects.
Novelty and Inventive Step
The new claims introduce a paradigm shift in opioid overdose rescue and prevention by integrating AI, wearable devices, and nanoparticle formulations. The inventive concept's novelty lies in its ability to provide personalized, proactive, and effective treatment solutions, which is non-obvious compared to the original patent's limitations.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include variations in the wearable device design, AI algorithmic approaches, and nanoparticle formulations. For example, the wearable device could be replaced with a mobile application or a implantable sensor, and the AI algorithm could be adapted for use in emergency response systems or healthcare provider networks.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the healthcare and pharmaceutical industries, particularly in the areas of opioid overdose prevention and treatment. The target market includes emergency responders, healthcare providers, and patients at risk of opioid overdose. The platform's ability to provide personalized and effective treatment solutions could lead to significant market share and revenue growth.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulations, medical device technologies, and drug delivery systems with a focus on opioid antagonist treatments and overdose prevention
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, pharmacology, or biomedical engineering, possessing expertise in drug formulation, medical device design, and knowledge of opioid pharmacodynamics
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of AI, wearable technologies, and nanoparticle delivery represents a predictable technological evolution of existing opioid antagonist treatment methods. The disclosed system combines known technologies in drug delivery, monitoring, and personalized medicine to address limitations in current overdose rescue approaches. The variations represent logical extensions of existing pharmaceutical and medical device technologies that would be apparent to a skilled practitioner seeking to improve opioid overdose interventions.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,547 |
|---|---|
| Title | Compositions and methods for opioid antagonist delivery |
| Assignee(s) | Purdue Pharma L.P. |